Teresa Bernal, Ainhoa Fernández Moreno, Almudena de LaIglesia, Celina Benavente, Ana García-Noblejas, Daniel García Belmonte, Rosalía Riaza, Olga Salamero, Maria Angeles Foncillas, Alicia Roldán, Víctor Noriega Concepción, Laura Llorente González, Juan Miguel Bergua Burgués, Soraya Lorente de Uña, Gabriela Rodríguez-Macías, Adolfo de la Fuente Burguera, Maria José García Pérez, Jose Luis López-Lorenzo, Pilar Martínez, Concepción Aláez, Marta Callejas, Carmen Martínez-Chamorro, José Rifón Roca, Lourdes Amador Barciela, Armando V Mena Durán, Karoll Gómez Correcha, Esperanza Lavilla Rubira, María Luz Amigo, Ferran Vall-Llovera, Ana Garrido, María García-Fortes, Dunia de Miguel Llorente, Anastasia Aules Leonardo, Carlos Cervero, Rosa Coll Jordá, Manuel M Pérez-Encinas, Marta Polo Zarzuela, Angela Figuera, Guillermo Rad, David Martínez-Cuadrón, Pau Montesinos
BACKGROUND: CPX-351 is approved for the treatment of therapy related acute myeloid leukemia (t-AML) and AML with myelodysplastic related changes (MRC-AML). The benefits of this treatment over standard chemotherapy has not been addressed in well matched cohorts of real-life patients. METHODS: Retrospective analysis of AML patients treated with CPX-351 as per routine practice. A propensity score matching (PSM) was used to compare their main outcomes with those observed in a matched cohort among 765 historical patients receiving intensive chemotherapy (IC), all of them reported to the PETHEMA epidemiologic registry...
May 22, 2023: Cancer Medicine